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Background: We reported previously that while prolonged tenofovir monotherapy of macaques infected with
virulent simian immunodeficiency virus (SIV) resulted invariably in the emergence of viral mutants with reduced
in vitro drug susceptibility and a K65R mutation in reverse transcriptase, some animals controlled virus replication
for years. Transient CD8+ cell depletion or short-term tenofovir interruption within 1 to 5 years of treatment
demonstrated that a combination of CD8+ cell-mediated immune responses and continued tenofovir therapy was
required for sustained suppression of viremia. We report here follow-up data on 5 such animals that received
tenofovir for 8 to 14 years.
Results: Although one animal had a gradual increase in viremia from 3 years onwards, the other 4 tenofovir-treated
animals maintained undetectable viremia with occasional viral blips (≤ 300 RNA copies/ml plasma). When tenofovir
was withdrawn after 8 to 10 years from three animals with undetectable viremia, the pattern of occasional episodes
of low viremia (≤ 3600 RNA/ml plasma) continued throughout the 10-month follow-up period. These animals had
low virus levels in lymphoid tissues, and evidence of multiple SIV-specific immune responses.
Conclusion: Under certain conditions (i.e., prolonged antiviral therapy initiated early after infection; viral mutants
with reduced drug susceptibility) a virus-host balance characterized by strong immunologic control of virus
replication can be achieved. Although further research is needed to translate these findings into clinical
applications, these observations provide hope for a functional cure of HIV infection via immunotherapeutic
strategies that boost antiviral immunity and reduce the need for continuous antiretroviral therapy.
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Considering the bleak prognosis for HIV-infected
patients during the early years of the epidemic, our
current ability to manage HIV infection with antiretro-
viral therapy (ART) and other supportive care represents
a triumph of research and modern medicine [1]. Despite* Correspondence: kkvanrompay@ucdavis.edu
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distribution, and reproduction in any mediumthe ongoing discovery of compounds with better efficacy,
safety and dosage regimens, long-term ART is still
complicated by issues such as cost, compliance and drug
resistance, which are often more pronounced in resource-
limited settings where treatment options are limited.
Accordingly, the quest continues to find strategies that
would reduce or totally eliminate the need for antiretro-
viral drugs. The observation that HIV-1 infection seems
to have been cured in the so-called Berlin patient byentral Ltd. This is an Open Access article distributed under the terms of the
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row transplant from a donor with the Δ32 CCR5 muta-
tion provided important proof-of-concept and has
initiated a “race for the cure” to develop drug-based
strategies to purge out viral reservoirs and ultimately
cure HIV infection, i.e. a sterilizing cure [2-4].
The ultimate goal of a practical, cheap and safe
method to completely cure HIV infection, however, is
likely to be years away. Therefore, an alternative goal is a
functional cure, in which virus is not eliminated but is
controlled sufficiently by antiviral immune responses so
that drug treatment can be withdrawn for prolonged
periods of time [4]. Because withdrawal of ART generally
leads to a rapid viral rebound, a variety of interventions
have been explored to boost immunological control
prior to ART withdrawal; these strategies include struc-
tured treatment interruptions, active immunization and
immune reconstitution strategies [5-8]. While many of
these strategies showed some modest efficacy, the bene-
fits were often variable or transient, or the strategy was
technically challenging. Accordingly, none of the immu-
notherapeutic strategies is yet ready to be implemented
beyond the confinement of closely monitored clinical
trials.
Simian immunodeficiency virus (SIV) infection of
macaques is a well-established animal model of HIV in-
fection. It has proved useful to gain a better understand-
ing of antiretroviral therapy and viral reservoirs, and to
explore the efficacy and durability of immunotherapeutic
strategies to help the immune system in controlling virus
replication (reviewed in [9]).
In a series of studies, we demonstrated previously that
prolonged tenofovir monotherapy of macaques infected
with virulent SIVmac251 or RT-SHIV resulted invariably
in the emergence of viral mutants with a K65R mutation
in reverse transcriptase [10-12]. Nonetheless, a signifi-
cant proportion of animals were able to eventually sup-
press plasma viremia to low or undetectable levels forTable 1 Summary of history of tenofovir-treated SIV-infected
Animal
number
Virus
inoculum a
Age of virus
infection
Start of
tenofovirb, c
CD8+ ce
depletion
29276 SIVmac-K65R 3 days 3 wks 316 wks
30577 RT-SHIV 19 months 20 wks 263 wks
32186 SIVmac251 17 months 2 wks 39 wks
33088 SIVmac251 12 months 2 wks 2 wks
33091 SIVmac251 12 months 2 wks 2 wks
a Animals were inoculated orally or intravenously with wild-type SIVmac251 or RT-S
isolate (SIVmac385) derived from tenofovir-treated SIVmac251-infected animals, as
(with sometimes transient blips). With exception of animal 33091, which eventually
or low viremia even after tenofovir withdrawal.
b Tenofovir was initially given to all these animals at a once-daily regimen of 30 mg
reductions to stable maintenance regimens, as described earlier [10,13,15].
c Times are expressed as weeks after SIV inoculation.
d Transient CD8+ cell depletion was performed by administration of the monoclonayears, with increasing difficulty to isolate virus in vitro
from lymphocytes obtained from blood or lymphoid tis-
sues. Such control of viremia was never observed in un-
treated animals infected with these wild-type or K65R
viruses [10,11,13-17]. Transient CD8+ cell depletion or
short-term tenofovir interruption within 1 to 5 years of
the onset of treatment demonstrated that a combination
of potent CD8+ cell-mediated immune responses and
continued tenofovir therapy was required for this sus-
tained suppression of viremia [10,11,13,15].
Here, we report follow-up data on a cohort of five
such animals that received tenofovir therapy for 8 to
14 years; this long duration of antiretroviral therapy is,
to our knowledge, unprecedented in the SIV macaque
model. We report that although one animal gradually
lost control on K65R virus replication while still on
tenofovir therapy, the other animals resembled long-
term non-progressors because their immune system
continued to control virus replication even after with-
drawal of tenofovir therapy.
Results
Historical overview of animals
As described in detail previously [10,11,13-15] and sum-
marized in Table 1 and Figure 1, five animals were
infected at birth or at juvenile age with either wild-type
SIVmac251 (n = 3), a K65R isolate derived from SIV-
mac251 (n = 1) or RT-SHIV (a chimeric SIV containing
HIV-1 RT). Subsequently, the animals were started on
prolonged tenofovir treatment, and all had been able to
reach undetectable plasma viremia. All animals had pre-
viously been depleted transiently of CD8+ cells by ad-
ministration of the anti-CD8 antibody cM-T807, either
early or late during the course of tenofovir therapy. Four
of the five animals had also received a short treatment
interruption that had resulted in an increase in viremia,
which became undetectable again when tenofovir ther-
apy was reinstated.macaques
ll
d
Temporary tenofovir
interruption
Permanent tenofovir
withdrawal
Time of
euthanasia
None None 736 wks
289 to 298 wks 552 wks 595 wks
64 to 71 wks 457 wks 498 wks
32 to 39 wks 425 wks 468 wks
32 to 39 wks 425 wks 466 wks
HIV, with the exception of animal 29276, which was inoculated with a K65R SIV
described previously [10,11,13]. All animals had reached undetectable viremia
had a gradual increase in viremia, all other animals maintained undetectable
/kg body weight, administered subcutaneously, with subsequent dosage
l antibody cM-T807 as described earlier [11].
Figure 1 Plasma viral RNA levels in infected macaques before
and during tenofovir treatment, and following tenofovir
withdrawal. Animals were infected with wild-type (wt) or K65R RT
viral mutants as described in Table 1. The shaded areas represent
periods of tenofovir treatment. Horizontal dotted lines represent the
consecutively lower detection limits of the viral RNA assays (500, 125,
30, 10 copies/ml) during the historical course of the experiments.
Van Rompay et al. Retrovirology 2012, 9:57 Page 3 of 17
http://www.retrovirology.com/content/9/1/57MHC class I typing
Animals were typed for MHC class I alleles that in
some studies correlated with lower viremia (Mamu-
A*01, -B*08, -B*17) or higher viremia (Mamu-B*01) of
some, but not all, SIV isolates, particularly SIVmac239
[18-21]. Their impact on control of other SIV isolates,
such as the SIVmac251 stocks used in the current study
is not clear [10]. In this study, we observed no consistent
pattern of protective alleles (Table 2). Two animals with
good virological control (numbers 29276 and 32186) had
none of the protective alleles; in contrast, the only animal
with two of the alleles (33091) was the one that gradually
lost control of virus replication (see further).Virological & clinical outcome
For consistency, we used a working definition of viral
blip quite similar to the one used commonly in humans
[22], but taking into account that we monitored animals
more frequently (sometimes more than once per week)
than humans: a viral blip was defined as a viral RNA
load measurement of 50–1000 copies/mL lasting less
than 3 weeks, that was preceded and followed by an-
other HIV RNA load measurement of <50 copies/mL.
Animal 29276 maintained undetectable viremia (< de-
tection limits of 10–15 RNA copies per ml plasma) from
week 322 onwards, with no detection of viral blipsTable 2 Typing of MHC class I alleles of SIV-infected
animals
Animal # A01 A02 A08 A11 B01 B03 B04 B08 B17 MHC
scorea
29276 - - - - - - - - - 0
32186 - - - - - - - - - 0
30577 + - - + - - - - - +1
33088 - - - - + - - + - 0
33091 + - - - - - - + - +2
CNPRC
frequency(%)b
18.8 13.8 13.0 9.1 29.9 1.2 1.5 7.1 11.2
aThe MHC score was calculated by adding one point for each protective allele
(Mamu-A*01, B*08, B*17) and subtracting a point for Mamu-B*01, which has
been associated with higher viral levels; other alleles are given a zero score
[18-21].
bFrequency of alleles in the general rhesus macaque colony of the California
National Primate Research Center; there was no statistically significant
difference in frequency between the 5 SIV-infected animals and the general
frequency for any of these alleles (p values> 0.5).
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blems, triggered by a prolonged high-dose tenofovir regi-
men during the first years of life, when the relationship
between drug levels and renal toxicity was still poorly
understood. Although the renal insufficiency was largely
managed by dosage reduction, it still progressed slowly,
as described previously [14,15]. However, at approxi-
mately 14 years of age (736 weeks of infection), while
still on tenofovir therapy, an adverse reaction to another
medication aggravated the renal toxicity and the animal
had to be euthanized. Tissues collected at time of eu-
thanasia showed low virus levels that were undetectable
or at the limit of detection (Table 4).
During tenofovir treatment, another 3 animals (30577,
32186 and 33088) continued to have mostly undetect-
able plasma viremia (below the cut-off of 10–30 copies
per ml), with occasional viral blips between 50 and 200
RNA copies/ml (Figure 1, Table 3). Testing of PBMC for
cell-associated virus showed that most samples had de-
tectable but low viral DNA levels, with occasional detec-
tion of low SIV RNA levels (Table 5).
Following tenofovir withdrawal on these 3 animals,
viremia remained largely undetectable with transient
blips. Animal 33088 fared the best, as viremia remained
consistently below 50 copies per ml (Figure 1; Table 5);
at 3 time points (at 1, 10 and 24 weeks of tenofovir with-
drawal) plasma viremia was detectable but very low (20
to 30 copies per ml), while at the 37 other time points,
viremia was below the detection limit (< 10–30 copies
per ml; Figure 1, Table 5). Tissues collected at time of
euthanasia had also very low or undetectable SIV RNA
and DNA levels (Table 4).
The other 2 animals (30577 and 32186) had intermit-
tent viral RNA blips> 50 copies/ml following tenofovir
withdrawal. For these 2 animals the frequency of viral
blips before and after withdrawal was similar (Table 3);
however, after tenofovir withdrawal, the magnitude wasTable 3 Analysis of viral blips in animals with low viremia du
During tenofovir treatment
Animal
numbera
Time window
(weeks of
infection)b
Number of
time points
for plasma
viral RNA
analysis
Number of
time points
with plasma
viral RNA≥
50 copies
per ml
Peak plasma
virus copies
per ml
(time point)
Time win
(weeks o
infection
29276c 598-736 16 0 NAc NAc
30577 299-552 39 12 270 (513 wks) 553-595
32186 316-457 39 4 300 (418 wks) 458 -498
33088 284-425 38 2 200 (386 wks) 426-468
a Animal 33091 had already developed moderate viremia near the end of tenofovir
b The time window of analysis during tenofovir treatment started as soon as more
until the day of tenofovir withdrawal; the time window after tenofovir withdrawal c
euthanasia.
c NA (not applicable); for animal 29276, plasma virus levels during this time period
plasma) and tenofovir treatment was not withdrawn.higher, as both animals had RNA levels exceeding 1,000
copies/ml at one time point each. Animal 30577 had an
initial detectable plasma viremia of 780 and 1,100
RNA copies per ml at 3 and 4 weeks after tenofovir
withdrawal, respectively. Subsequently, viremia became
undetectable for 11 consecutive weeks, followed by 2
transient blips (120 and 350 copies per ml at 16 and
32 weeks after withdrawal, respectively; Figure 1,
Table 5). At the time of euthanasia (43 weeks after
tenofovir withdrawal), animal 30577 had undetectable
plasma viremia (< 10 copies/ml); while most tissues had
detectable viral DNA, none had detectable viral RNA
(Table 4).
Animal 32186 had several viral blips> 50 copies per
ml after tenofovir withdrawal (Figure 1). An abrupt in-
crease from undetectable (< 10 copies/ml at week 36
after withdrawal) to peak levels of 3,600 copies/ml (week
37 after withdrawal) was observed, after which virus
levels decreased gradually to 20 copies/ml when the ani-
mal was euthanized at 41 weeks after tenofovir with-
drawal (Figure 1, Table 5). Most tissues had low virus
levels, with exception of the tonsil that had high SIV
DNA and RNA levels (Table 4). Although the tonsil had
normal histology and the animal did not have overt clin-
ical signs, it is speculative that the animal may have had
a pharyngeal infection, resulting in local immune activa-
tion and virus replication, approximately a month before
euthanasia.
The last animal of the cohort, animal 33091, had a dis-
tinct outcome. After a 3-year period of undetectable
plasma viremia (weeks 45–207 of SIV infection), this ani-
mal developed a gradual increase in viremia despite con-
tinued tenofovir treatment (Figure 1). When tenofovir
was then withdrawn, instead of an abrupt viral rebound,
viremia continued its gradual increase and was approxi-
mately 10-fold higher when the animal was euthanized
10 months later (Figure 1; Table 5). Virus could bering tenofovir treatment and after tenofovir withdrawal
After tenofovir withdrawal
dow
f
)b
Number of
time points
for plasma
viral RNA
analysis
Number of
time points
with plasma
viral RNA
≥ 50 copies
per ml
Peak plasma
virus copies
per ml
(time point)
One-sided p value for
frequency of viremia≥
50 copies/ml during
versus after tenofovir
treatment
NAc NAc NAc NAc
wks 40 7 1,100 (556 wks) p= 0.13
wks 40 9 3,600 (494 wks) p= 0.13
wks 40 0 30 (435 wks) p= 0.23
therapy and was therefore excluded from this analysis.
sensitive assays for viral RNA (with sensitivity< 10–30 copies/ml) were used
overs from 1 week after withdrawal (i.e., the earliest sample) to the time of
were consistently below the limit of detection (<10-15 RNA copies per ml
Table 4 Virus levels in blood and tissues at time of euthanasia
Animal number Plasma PBMC Spleen Ax LN Ing LN Mes LN Thymus Tonsil Jejunum Colon
RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA DNA RNA
29276 <15 4 <2 2 1 3 2 3 <2 <1 <1 NA NA NA NA NA NA NA NA
30577 < 10 7 <2 <3 <3 4 <1 4 <1 7 <2 <2 <2 3 <1 <2 <2 2 <2
32186 20 15 <1 5 <1 40 9 7 90 30 200 <70 160 300 13,500 60 7 10 50
33088 < 10 6 <1 2 <1 8 10 4 1 5 3 <2 <2 3 1 <2 <2 <4 <4
33091 530,000 280 470 370 5,700 320 13,000 340 11,000 520 10,000 <2 50 570 30,000 60 640 50 160
Cell-free levels in plasma are expressed as RNA copies per ml plasma. Cell-associated levels are expressed as number of viral RNA and DNA copies per 100,000 cell equivalents (determined by total copy number of
CCR5 divided by two). < indicates below limit of detection (based on the detection limit of 30 viral RNA or DNA copies per reaction and the cell equivalents for the particular sample).
Ax LN= axillary lymph node, Ing LN= inguineal lymph node; Mes LN=mesenteric lymph node; NA =not available.
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Table 5 Summary of plasma and PBMC-associated virus levels shortly before and after tenofovir withdrawal
30577 32186 33088 33091
Plasma PBMC Plasma PBMC Plasma PBMC Plasma PBMC
Time after tenofovir
withdrawal
RNA DNA RNA RNA DNA RNA RNA DNA RNA RNA DNA RNA
- 24 wks < 10 4 1 < 10 1 < 1 < 10 4 4 4,300 20 5
- 12 wks < 15 7 2 < 10 < 1 < 1 < 15 3 < 1 38,000 20 20
- 4 wks 170 8 < 2 < 30 < 1 < 1 < 30 4 1 42,000 80 80
0 < 15 < 3 < 3 20 < 1 < 1 < 15 < 3 < 3 62,000 30 30
3 wks 780 < 2 < 2 20 < 3 < 3 < 15 < 3 < 3 120,000 60 50
4 wks 1,100 < 3 6 30 < 3 < 3 < 15 4 3 53,000 140 70
8 wks < 30 7 2 < 30 1 2 < 30 3 8 41,000 50 130
12 wks < 12 2 < 1 < 12 1 < 1 < 12 4 < 1 130,000 50 50
16 wks 120 8 < 1 20 4 < 1 < 12 7 < 1 70,000 90 20
24 wks < 10 10 < 3 < 10 6 < 4 20 9 < 4 100,000 200 160
32 wks 350 4 < 1 < 10 3 < 1 < 10 5 2 170,000 150 270
36 wks 15 7 < 1 < 10 7 < 3 < 10 3 < 1 310,000 170 120
37 wks < 10 5 < 1 3,600 9 < 4 < 10 2 < 1 460,000 160 110
39 wks < 10 10 < 6 470 15 < 3 < 10 7 7 550,000 180 430
40 wks 20 4 < 1 320 7 < 4 < 10 2 < 1 650,000 180 290
41-43 wksa < 10 7 < 2 20 15 < 1 < 10 6 < 1 530,000 280 470
Cell-free levels in plasma are expressed as RNA copies per ml plasma. Cell-associated levels are expressed as number of viral RNA and DNA copies per 100,000 cell
equivalents. Values are given relative to the time of permanent tenofovir withdrawal (=time zero). Results of samples from other time points that are not shown in
these tables were used for the analysis of Table 3.
aValues for 41–43 weeks after tenofovir withdrawal are those at the time of euthanasia.
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amounts in lymph nodes and tonsil (Table 4).Quantitation and genotypic analysis of K65R viral
mutants
Real-time PCR methodology and population sequencing
was used to monitor and quantitate K65R viral mutants
after tenofovir withdrawal. For the animals with very low
viremia, the plasma and tissue samples with the highest
viral RNA were selected for this analysis. While plasma
viral RNA levels in animals 30577, 33088 and 32186
were too low to amplify, viral RNA in the tonsil of ani-
mal 32186 revealed a pure K65R population with the
additional RT mutations of N69S, I118V; these muta-
tions were found previously in this animal [10]. For ani-
mal 33091, plasma collected at the time of tenofovir
withdrawal and at the time of euthanasia (41 weeks after
tenofovir withdrawal) had pure K65R populations; most
other RT mutations were found in both samples (N69S,
Y115F, I118V, D121H, V201A, S211N), while some
mutations were found in only 1 sample (K40E and
R82R/K at time of tenofovir withdrawal; K43E at time of
euthanasia). Nearly all of these mutations have been
described previously in K65R SIV isolates of animal
33091 and other tenofovir-treated animals [10,12,13,23].In summary, there was no evidence of reversion from
K65R to wild-type virus after tenofovir withdrawal.Frequency of lymphocyte populations and SIV-specific T
cell responses correlate with levels of SIV replication
Throughout the time of tenofovir treatment and also
after tenofovir withdrawal, the animals with suppressed
viremia (29276, 30577, 32186 and 33088) maintained
normal total lymphocyte counts, percentages and abso-
lute values of CD4+ and CD8+ T lymphocytes, B lym-
phocytes and NK cells, and CD4+/CD8+ T cell ratios in
peripheral blood (data not shown).
Animal 33091, consistent with its gradual increase in
viremia, displayed a slowly progressive reduction in per-
centage and absolute CD4+ T lymphocytes and CD4/
CD8 T cell ratio and an increase in the percentage of B
lymphocytes in peripheral blood. At the time of tenofo-
vir withdrawal, the animal had 9% CD4+ T lymphocytes
(normal, mean +/− SD: 34-44%), 390 CD4+ T cells/μl
(normal, mean−/+ SD: 325–785; a CD4/CD8 T cell ratio
of 0.66 (normal range: 0.9-3.0); and 67% B lymphocytes
(normal, mean −/+ SD: 25-38%). There was little change
following tenofovir withdrawal and at the time of eu-
thanasia, the corresponding values were 10.5% CD4+ T
lymphocytes, 129 CD4+ T cells/μl; CD4+/CD8+ T cell
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CD8+ T lymphocytes and NK cells of animal 33091 were
within the normal range, while absolute values were
more variable (data not shown).
Blood and tissues collected at time of euthanasia were
available from 4 animals and used for more detailed
lymphocyte phenotyping. As activated memory CD4+ T
cells represent the main target cells of SIV, we examined
the percentage of naïve T cells (CD28 +CD95-), central
memory cells (CD28 +CD95+), and effector memory
and effector cells (CD28-CD95+) (Figure 2). Compared
to three uninfected age-matched adult macaques, and
despite much variability among animals and tissues, the
SIV-infected animals showed a trend towards lower
CD4+ T cell populations in some tissues (such as total
CD4+ T cells in jejunum; central memory CD4+ cells in
the lymph nodes, and effector and effector memory
CD4+ cells in peripheral blood), and a conversely higher
percentage of CD8+ T cells and naïve CD4+ T cells in
those tissues (Figure 2). Consistent with the moderate
viremia, animal 33091 showed the lowest numbers of
CD4+ T cells.Figure 2 T cell memory phenotyping of SIV-infected rhesus macaque
T cells (E-H) from PBMC and tissue lymphoid cells collected at time of euth
compared to those of 3 uninfected animals. Data are reported as the frequ
population, or as the frequency of naïve cells, CD28 +CD95- (B,F), central m
cells, CD28- (D,H) within their respective CD4+ and CD8+ T cell populationThe frequency and quality of CD4+ and CD8+ SIV-
specific responses were examined by measuring intra-
cellular cytokines after ex vivo stimulation assay with
SIVmac239 gag peptides and chemically-inactivated
SIVmac239 (AT-2) (Figure 3). All SIV-infected animals
had CD4+ and CD8+ SIV-specific responses to both
stimuli, but the tissue distribution and range of function-
ality differed between animals. Viremic animal 33091 had
less of a multifunctional response with more of the
responding cells positive for only one cytokine compared
to the other SIV-infected animals. Interestingly, animal
33091 lacked SIV-specific T cell responses in intestinal
tissues compared to the other 3 SIV-infected animals that
had better control of viremia (Figure 3).
Loss of T cell function is often associated with T cell
exhaustion. In fact, previous studies have demonstrated
that chronic SIV infection is associated with the loss of
the proliferation and the ability to produce cytokines, es-
pecially interleukin-2 [24,25], while the co-inhibitory
molecule PD-1 is increased. Although all animals had a
trend towards higher T cell exhaustion compared to un-
infected animals, animal 33091 showed the highest levels after tenofovir withdrawal. CD3+ 4+ T cells (A-D) and CD3+ 8+
anasia were assessed via multiparameter flow cytometry. Values were
ency of CD4+ T cells (A) and CD8+ T cells (E) in the total lymphocyte
emory cells, CD28+CD95+ (C,G), and effector and effector memory
s. Animal 33091 is represented as a red square in all graphs.
Figure 3 SIV-specific T cell responses. The response of CD3+CD4+ (A, B) and CD3+CD8+ (C, D) T cells after stimulation of PBMC or lymphoid
cells with AT-2 (A,C) or SIVgag p27 overlapping peptides (B,D) and assessed for production of intracellular cytokines. Data are expressed as the
frequency of cells positive for a set of cytokines, with tissue-specific responses represented by different colors: axillary lymph node (green),
jejunum (red), mesenteric lymph node (blue), PBMC (white), spleen (black).
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SIV-specific T cell responses. Consequently, animal
33091 also had the highest frequencies of T cells under-
going apoptosis (Figure 4).Evaluation of SIV-specific antibody responses
Plasma of the 5 SIV-infected animals was tested by SIV-
specific IgG ELISA for the detection of binding antibodies.
All animals had measurable binding antibodies during
tenofovir treatment (titers≥ 409,600), with viremic animal
33091 having the highest titer (Table 6). For the 4 animals
from which tenofovir was withdrawn, plasma of at least 12
time points after withdrawal was tested by ELISA, but
SIV-binding antibody titers did not change significantly
over time (Table 6).
Serum samples were tested for neutralizing antibodies in
a single-round infection assay that measures a reductionin luciferase reporter gene expression. Undetectable or
very low titers of neutralizing antibodies were observed
against env-pseudotyped viruses or human PBMC-grown
SIVmac251. However, high titers of neutralizing antibodies
were detected against laboratory adapted SIVmac251, and
for animals 30577 and 33088, there was a more than 4-
fold increase in titer from the time of tenofovir withdrawal
to the time of euthania 43 weeks later (Table 6).
Serum samples were also tested for antibody-dependent
cell-mediated virus inhibition (ADCVI), an antibody func-
tion that inhibits virus yield from infected cells in the
presence of Fc-receptor bearing cells. All sera collected at
the time of tenofovir withdrawal and at the time of eu-
thanasia had very high ADCVI activity against all viruses
tested, including viral stocks that were grown in human or
rhesus PBMC (Table 6). There was no difference in
ADCVI titers in sera of viremic animal 33091 in compari-
son to the other animals that controlled viremia.
Figure 4 T cell apoptosis and exhaustion phenotype in SIV-infected rhesus macaques after tenofovir withdrawal and uninfected
macaques. CD3+ 4+ T cells (A, C) and CD3+ 8+ T cells (B, D) from PBMC and tissue lymphoid cells were assessed via multiparameter flow
cytometry for apoptotic cells, Caspase3 + Bcl2-, (A, B) and exhausted cells, PD-1 + Bcl2- (C, D). Data are reported as the frequency of the
aforementioned cell populations in the CD4+CD3+ or CD3+CD8+ T cell populations, and are compared to those of 3 uninfected animals.
Animal 33091 is represented as a red square in all graphs.
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Viremic animal 33091, despite having a normal clinical
appearance (normal weight, no overt evidence of oppor-
tunistic infections) had histological evidence of an inter-
mediate stage of SIV disease progression, characterized
by lymphoid hyperplasia and depletion and endocarditis
(Table 7). In contrast, the 4 other SIV-infected animalswith low or undetectable virus levels had no or mild
lymphoid changes.
As described in detail previously [14,15], animals
29276 and 32186 had a long clinical history of renal tox-
icity caused by an initial prolonged high-dose tenofovir
regimen, and potentially complicated by CD8+ cell de-
pletion; despite relative stabilization after dosage
Table 6 SIV-specific antibody responses in plasma at the end of tenofovir treatment and after tenofovir withdrawal
SIV-specific binding IgG1 Neutralizing antibody ID50 in TZM-bl cells2 ADCVI3
% inhibition of 1:100 serum dilution
Animal number Time point SVA-MLV SIVmac239CS.23 SIVmac251-CS SIVmac251-TCLA SIVmac251-CS SIVmac251-TCLA SIVmac251 (UCD) RT-SHIV
29276 Euthanasia 409,600 20 <10 17 29,462 48.89 99.98 99.99 nd
30577 TFV withdrawal 409,600 <10 <10 12 380,644 61.77 99.94 93.49 99.89
“ Euthanasia 409,600 <10 13 11 >1,562,500 33.29 99.94 94.48 99.89
32186 TFV withdrawal 1,638,400 <10 <10 10 >1,562,500 99.98 99.98 99.99 nd
“ Euthanasia 1,638,400 <10 <10 <10 >1,562,500 99.98 99.98 99.06 nd
33088 TFV withdrawal 409,600 <10 <10 13 451,911 99.98 99.98 99.99 nd
“ Euthanasia 409,600 <10 <10 <10 >1,562,500 99.78 99.98 99.99 nd
33091 TFV withdrawal 6,553,600 <10 <10 10 >1,562,500 99.98 99.98 99.99 nd
“ Euthanasia 6,553,600 <10 <10 12 >1,562,500 99.98 99.98 99.99 nd
1Values of SIV-binding antibody titers are the reciprocal of the highest plasma dilution (of 4-fold dilutions) that gave a positive signal on whole-virus antibody ELISA assay specific for IgG.
2Values of neutralizing antibody are the serum dilution at which relative luminescence units (RLUs) were reduced 50% compared to virus control wells (no test sample); viruses tested were pseudoviruses
SIVmac239CS.23 and SVA-MLV grown in 293 T cells, and replication-competent SIVmac251-CS (hPBMC-grown) and uncloned SIVmac251-TCLA (H9-grown; tissue culture lab adapted).
3ADCVI: antibody-dependent cell-mediated virus inhibition was tested at a 1:100 serum dilution with SIV-infected CEM.NKr R5 as targets and human PBMC as effector cells. The reported values of % inhibition are the
averages of 2 independent experiments. The SIVmac251CS and SIVmac251-TCLA are the same as those used in the neutralizing antibody assay; SIVmac251 (UCD) is a stock grown in rhesus PBMC derived from the
same seed stock as the SIVmac251 stock that was used to inoculate animals 32186, 33088 and 33091. The RT-SHIV stock was grown in rhesus PBMC from the same seed stock used to infect animal 30577. Only serum
of RT-SHIV infected animal 30577 was tested for ADCVI activity against RT-SHIV. nd indicates not done.
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Table 7 Pathological observations at time of euthanasia
Animal number Most significant findings
29276 Chronic interstitial nephritis with tubular atrophy
Hypophosphatemic osteomalacia
Mild generalized lymphoid hyperplasia
30577 Lymphofollicular hyperplasia, mild (inguinal, axillary,
tracheobronchial, and mesenteric
lymph nodes; MALT (mucosa-associated lymphoid
tissue) of cecum and stomach) to
moderate (tonsil, spleen, ileocecocolic lymph nodes).
32186 Kidney: polycystic chronic interstitial nephritis with
tubular atrophy
Lymph nodes: mild paracortical hyperplasia and
mild loss of germinal centers
33088 Mild multifocal hepatitis, mild colitis, mild tracheitis
33091 Heart: valvular vegetative endocarditis
Bone marrow and ileum: moderate multifocal
lymphoid hyperplasia
Lymph nodes: mild to moderate paracortical
hyperplasia with indistinct germinal centers
Spleen: mild lymphoid depletion
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ical findings of glucosuria and elevated serum creatinine
levels, the kidneys of both these animals showed chronic
interstitial nephritis with tubular atrophy.
In contrast, the other 3 tenofovir-treated animals
(30577, 33088 and 33091) had normal urinary and
serum chemistry values, and had no gross or histopatho-
logical evidence of renal toxicity. This lack of detectable
toxicity is reassuring considering that these animals were
treated for many years with tenofovir regimens that gave
exposures (as determined by plasma AUC values) higher
than those of the clinical dose of tenofovir given to
humans [15].Discussion
The current report is a follow-up study of 5 animals that
received prolonged tenofovir monotherapy. Despite the
emergence of K65R viral mutants with 5-fold reduced
in vitro susceptibility, all five animals had eventually
reached undetectable viremia [10,11,13,15]. Although we
and others have previously described low or undetect-
able viremia after the emergence of K65R viral mutants
in tenofovir-treated animals [12,26], the uniqueness of
the present cohort of 5 animals resides in the unprece-
dented extensive period of tenofovir therapy (8 to
14 years) and survival. These animals were infected with
virulent virus, and animals infected with these same
viruses (wild-type or K65R) but not receiving any anti-
viral drug therapy were never able to spontaneously sup-
press viremia to low or undetectable levels and generallydeveloped symptoms of AIDS within 2–24 months
[10,11,13,15].
It is remarkable that during tenofovir treatment last-
ing 8 to 14 years, 4 of the 5 tenofovir-treated animals
continued to have undetectable viremia with occasional
viral blips. Similarly to observations in humans [27], the
reasons for viral blips were not clear but may reflect a
transient increase in viral production (e.g., due to im-
mune activation) and/or minor fluctuations in antiviral
effector mechanisms. Overall, the sustained suppression
of virus replication in the 4 animals testifies to the
strength of antiviral immune responses that were docu-
mented previously via CD8+ depletion experiments
[10,11]. In other SIV studies, including many vaccine
studies, animals that initially controlled replication of
virulent virus often showed an increase in viremia after
prolonged follow-up [28-31]. As explained in more de-
tail elsewhere, it is plausible that, whereas as no single
factor may be sufficient, a synergistic combination of (i)
effective antiviral immune responses, preserved by early
initiation of treatment, and sustained by ongoing low-
level replication of K65R virus, (ii) a minor effect of
K65R and compensatory mutations on viral replication
fitness or diversity, and (iii) some residual drug efficacy
against K65R mutants was responsible for a steady-state
situation without viral rebound in these tenofovir-
treated animals [9-11]. The demonstration that a com-
bination of tenofovir and antiviral immune responses
can suppress K65R SIV replication in macaques for
many years is also consistent with the lack of viral re-
bound in treatment-experienced patients who develop
K65R viral mutants during tenofovir treatment, and the
observations that viremia in persons with detectable
K65R mutants can be suppressed by tenofovir-
containing regimens [32-34].
An exception was animal 33091, which despite having
nearly 3 years of undetectable plasma viremia, slowly lost
control of virus replication and demonstrated a slow dis-
ease progression while still on tenofovir treatment. It is
unknown whether the transient CD8+ depletion that was
performed previously in this animal at 2 weeks of SIV in-
fection, when antiviral immune responses were in their
early stages and probably most vulnerable, may have had
a negative impact on the strength and breadth of the
antiviral CD4+ or CD8+ cell repertoire, predisposing the
eventual outgrowth of viral immune escape variants. In
contrast, three of the four animals that demonstrated
sustained suppression of viremia during tenofovir treat-
ment had been depleted of CD8+ cells during a later
stage of infection (≥ 39 weeks), when viremia was already
suppressed by strong antiviral immune responses, and
when the immune perturbation caused by CD8+ deple-
tion may have had only a transient impact on antiviral
immune responses.
Van Rompay et al. Retrovirology 2012, 9:57 Page 12 of 17
http://www.retrovirology.com/content/9/1/57For 3 of the 4 animals with sustained suppression of
viremia during tenofovir treatment, the treatment was
eventually stopped. Despite some transient periods of de-
tectable low viremia, no rapid viral rebound was observed
during the 10 months of observation. These animals that
controlled viremia after tenofovir withdrawal also had low
levels of viral DNA in blood and lymphoid tissues, stable
CD4+ cell counts and a broad variety of cellular and
humoral antiviral immune responses. These observations
recapitulate the features of long-term non-progressor
(LTNP’s), who naturally suppress virus replication for pro-
longed periods of time without antiretroviral drug inter-
vention (reviewed in [35]).
The absence of a rapid rebound in all three animals
can theoretically be due to low replication fitness of the
virus, to strong antiviral immune responses, or to a
combination of both. Previous experiments demon-
strated that SIV and RT-SHIV isolates having the K65R
mutation in combination with compensatory mutations
have high replication fitness and virulence, and generally
do not revert back to wild-type sequence following teno-
fovir withdrawal [10,11,13,16,17]. Also in the current
study, withdrawal of tenofovir treatment did not lead to
a detectable reversion from K65R to wild-type virus. Ac-
cordingly, the absence of a viral rebound likely repre-
sents an effective immune-mediated control of virus
replication, rather than a major replication-attenuated
phenotype. The development and maintenance of the
cellular and humoral immune responses we observed
must have been promoted by ongoing low-level replica-
tion of K65R viral mutants during the prolonged period
of tenofovir treatment which created a balanced antigen
expression/immune response steady-state.
Previously, depletion experiments revealed a major
role for CD8+ cell-mediated immune responses in
suppressing virus replication during tenofovir treat-
ment in all 5 animals [10,11]. Because the cM-T807
antibody depletes both the CD8 +CD3+ T cells and
the CD8 +CD3- NK cells, the relative contribution of
these two cell subsets could not be established in
those studies. As NK cells are also effector cells of
ADCVI [36], they may play some role considering that
the sera of all animals had high ADCVI activity, even
against SIV strains that were poorly neutralized in the
absence of effector cells. Even though animal 33091’s
serum samples exhibited similarly high ADCVI activ-
ity in vitro as the other animals, it is unclear whether
a reduced function of ADCVI effector cells in vivo
contributed to its poorer control of virus replication.
Additional CD8+ cell depletion experiments during
the tenofovir-free period were not feasible because all
five animals had developed antibodies against the cM-
T808 antibody and other available CD8+ depleting
antibodies (data not shown).All SIV-infected animals had SIV-specific CD4+ and
CD8+ cell-mediated responses. Although there was
much variability in the functionality and tissue distribu-
tion among the different animals, the controlling ani-
mals had a trend towards a more multifunctional
response that was located particularly in the intestinal
tissues and lymph nodes, suggestive of an immunological
control of virus replication. In contrast, animal 33091’s
response was more mono-functional, absent in the intes-
tinal tract, and residing predominantly in the peripheral
blood, suggestive of an antigen-exposure driven immune
response. These patterns are consistent with observa-
tions in other studies [37].
A closer look at the historical data of this cohort and
other studies suggests several trends in the evolution of
the immunological control of virus replication. Firstly, as
shown in Figure 1, the viral rebound or blips shortly after
tenofovir interruption in some animals in the current
study were generally smaller than those observed with
short-term treatment interruption (7 to 9 weeks) on
these same animals earlier during the course of infection.
In other animal studies, treatment interruptions also
resulted in more rapid or higher viral rebound [10,38-54].
These observations suggest that the antiviral immune
responses in these K65R virus-infected animals strength-
ened – rather than weakened- during the consecutive
years of tenofovir treatment. Although this observation of
strengthening immune responses provides hope, the time
frame during which this was observed in the current study
also highlights a research dilemma: future studies aimed
at a functional cure, whether in animal models or human
cohorts, may require a duration of more than 5 to 10 years,
and therefore, a long-term investment in funding by
research agencies.
Secondly, the optimism of the current results needs
to be balanced with caution: although the frequency
of low plasma RNA levels during the 10 months off
tenofovir was similar to that during the prior period
of tenofovir treatment, the magnitude of viremia was
at times higher than what was observed during the
preceding 5 years on tenofovir therapy. This is con-
sistent with our previous observations that despite
strong antiviral immune responses, there is still some
benefit of continued tenofovir treatment, either by a
residual direct antiviral effect and/or by immunomo-
dulatory effects (reviewed in [9]). Although in the
current study each transient increase of viral RNA
was followed by a period of regained control, it is
possible that during a much longer drug-free observa-
tion period such blips may become higher or more
frequent and may require reinitiation of antiretroviral
therapy to prevent disease progression.
It has to be re-emphasized that this cohort of animals
had unique circumstances, namely prolonged tenofovir
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presence of K65R viral mutants resulting in the gener-
ation and maintenance of effective antiviral immune
responses and creation of a relative steady-state balance.
Therefore, these results may not apply to HIV-infected
patients who are started on ART late during infection,
effectively control viremia and do not develop drug-
resistant viral mutants. Such patients will typically show
a rapid viral rebound upon drug withdrawal, possibly in-
dicating insufficient antigenic exposure to generate, re-
store or maintain antiviral immune responses [55-58].
Consistent with our observation in monkeys, a minority
of patients (5 out of 32) started on ART during primary
HIV infection had good immunologic control of viremia
after ART interruption, and these controllers had a trend
toward earlier initiation and a longer duration of ART in
comparison to noncontrollers or transient controllers [59].
The cohort of animals described here shares similarities
with HIV-infected humans who, despite the presence of
multi-drug resistant viral mutants, have low viremia asso-
ciated with strong antiviral immune responses [60,61]. A
difference, however, is that in the HIV-infected patients,
interruption of nucleoside reverse transcriptase RT inhibi-
tors led to an immediate and persistent increase in viremia
and a reduction in CD4+ cell counts [62-64]. Potential
reasons for this difference include (i) later initiation of
ART, (ii) a much shorter duration of treatment, (iii) per-
sistent detectable viremia (> 400–1000 copies/ml) while
on ART (indicating less effective antiviral immune
responses even prior to drug withdrawal), and (iv) regi-
mens without tenofovir, which in addition to its antiviral
activity has shown unique immunomodulatory properties
in animal models [65,66].
For all these reasons, our results do not support with-
drawing ART in HIV-infected individuals.
Conclusions
By demonstrating a strong degree of viremia control
associated with virus-specific immune responses follow-
ing removal of antiviral drug treatment, the current
study provides hope for an eventual functional cure, but
warrants that much more research is required [4]. Ani-
mal models can continue to play a vital role in the devel-
opment and screening of such strategies and to help
advance concepts toward this functional cure.
Methods
Animals, virus inoculation, and tenofovir administration
All animals were rhesus macaques (Macaca mulatta)
housed at the California National Primate Research Cen-
ter (CNPRC), in accordance with American Association
for Accreditation of Laboratory Animal Care Standards.
We strictly adhered to the "Guide for the Care and Use
of Laboratory Animals" prepared by the Committee onCare and Use of Laboratory Animals of the Institute of
Laboratory Resources, National Resource Council [67].
Animals were inoculated intravenously or orally with
virulent uncloned SIVmac251, the K65R-containing
virus SIVmac385 (which is derived from SIVmac251), or
RT-SHIV as described in their original studies [10,11,13].
Tenofovir was administered subcutaneously once daily,
first at a regimen of 30 mg/kg, but doses were gradually
reduced to a low maintenance regimen that gave plasma
tenofovir concentrations and intracellular tenofovir di-
phosphate concentrations similar to or slightly higher
than those observed in humans taking the oral prodrug
tenofovir disoproxyl fumarate [15].Collection and processing of blood and tissue specimens
When necessary, animals were immobilized with keta-
mine HCL (Parke-Davis, Morris Plains, New Jersey)
10 mg/kg injected intramuscularly. Blood samples were
collected regularly for monitoring viral and immunologic
parameters as described previously [10]. Complete blood
counts were performed on EDTA-anticoagulated blood
samples. Samples were analyzed using an automated
electronic cell counter (Baker 9000; Serono Baker Diag-
nostics) and from November 2002 onwards, a Pentra
60 C+ analyzer (ABX Diagnostics); differential cell
counts were determined manually.
Lymphoid tissues collected at euthanasia were pro-
cessed to obtain cell suspensions by dissecting them with
scalpels in RPMI 1640 (Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS; Gemini
BioProducts, Calabasas, CA) (complete RPMI) and pas-
sing the cell homogenate through a cell strainer (Fisher,
Pittsburgh, PA). Mononuclear cells were isolated from
the splenic cell suspensions and the blood by density
gradient centrifugation with Lymphocyte Separation
Medium from MP Biomedicals (Aurora, OH), followed
by two washes with RPMI 1640.
Cell isolation from intestinal tissues was performed
according to previously described methods [68]. Briefly,
~2 in. pieces of the ileum and colon were rinsed with PBS
and then minced using sterile scalpels. The tissue suspen-
sions were placed in a shaking waterbath in RPMI 1640
containing 7.5% FBS and collagenase type II (0.5 mg/ml)
for 30 minutes at 370 C. After the digestion, the single cell
suspension was passed through a 100 μm filter, spun down
and resuspended in PBS. The remaining undigested tissue
was resuspended in collagenase-media and the digestion
step was repeated a total of 3 times. Mucosal lymphocytes
were then isolated from the obtained single cell suspen-
sion by performing a 35%/60% Percoll (Sigma) gradient
centrifugation. Intestinal lymphocytes were collected from
the 35%/60% interface and washed twice with PBS before
being resuspended in 10% FBS in RPMI 1640.
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Earlier data on plasma RNA levels in these animals were
determined by quantitative branched-chain DNA (bDNA)
assay for SIV, while the later plasma samples were tested
by real-time reverse transcription-polymerase chain re-
action (RT-PCR) assay for SIV gag, as described previously
[10,11,69].
To determine cell-associated viral RNA and DNA
levels, cell pellets of approximately 2 million PBMC or
lymphoid cells isolated from lymphoid tissues at time of
euthanasia were snapfrozen and stored at -70 °C. The
cell pellets were subsequently tested for SIV gag RNA
and DNA and CCR5 DNA (as a reference for cell
equivalents, because of 2 copies of CCR5 per cell)
according to methods described previously [70].
Real-time PCR for sensitive detection of K65R viral
mutants
The real-time PCR methodology to quantitate K65R
mutants of SIV and RT-SHIV has been described previ-
ously [11,71].
MHC typing
MHC typing for 9 class I alleles (Mamu-A*01, A*02,
A*08, A*11, B*01, B*03, B*04, B*08, B*17) was performed
using methods previously described [19,72].
Phenotyping of lymphocyte populations
Multiparameter flow cytometric analysis was performed
to characterize lymphocyte populations in PBMC and
tissue cell suspensions. All antibodies were from BD
Biosciences (San Jose, CA) unless otherwise stated. To
define T and B lymphocytes and NK cells, 4-color flow
cytometry techniques, consisting of a single tube con-
taining antibodies to CD3, CD4, CD8 and CD20, were
used and samples were analyzed on a FACSCalibur flow
cytometer, as described previously [10]. CD4+ T lym-
phocytes, CD8+ T lymphocytes, NK cells and B cells
were defined as CD4+CD3+, CD8+CD3+, CD8+CD3-
and CD20 +CD3- lymphocytes, respectively.
In different tubes, T cell sub-populations of CD3+
(clone SP34-2) and CD4+ (clone L200) or CD8+ (clone
SK1) T cells were further defined by markers of memory
[CD28 (clone CD28.2) and CD95 (clone DX2)] and
apoptosis [PD1 (clone J105, eBioscience), Bcl-2 (clone
Bcl-2/100), and Caspase 3 (clone C92-605)]; samples
were acquired on a FACS ARIA (BD), and data were
analyzed using FlowJo software (TreeStar, Ashland, OR).
Data are reported as the frequency of lymphocytes that
stained positive for a defined set of markers.
Antigen-specific stimulation of lymphocytes
Intracellular cytokine production was assessed via multi-
parameter flow cytometry from fresh PBMC andlymphoid cells after stimulation with SIV antigens as
reported previously [73]. Briefly, 1x106 cells per tube
were stimulated with 300 ng/mL aldrithiol-2 (AT-2)-
inactivated whole SIVmac239 (provided by Dr. J. Lifson,
NCI) or with 5 μg/mL of a pool of overlapping 15-mer
peptides spanning the SIVgag p27 protein (provided by
the NIH Reference and Reagent Program). PMA
(50 ng/mL, Sigma) and ionomycin (1 μg/mL, Sigma) were
used as a positive control. Cells were stimulated in the
presence of anti-CD49d, anti-CD28 (0.5 μg/mL each) and
monensin (2 μM; eBioscience). Cells were incubated at
37 °C in 5% CO2 for 6 hours, and after 1 hour, Brefeldin A
(10 μg/mL) was added. After stimulation, cells were
stained with the following antibodies following BD stain-
ing protocols: CD3 (clone SP34-2), CD4 (clone L200), IL2
(clone MQ1-17 H12), TNF-α (clone MAB11), IFN-γ
(clone B27), and IL17a (clone eBio64CAP17, eBioscience).
Samples were acquired on a FACS ARIA (BD), and data
were analyzed using FlowJo software (TreeStar, Ashland,
OR). Data are reported as the frequency of CD3+CD4+
or CD3+CD4- T cells that stained positive for a defined
combination of intracellular cytokines. Frequency values
were considered positive if they were 2-fold greater than
that of medium-only cultures and if the subtracted value
of stimulation cultures minus media-only cultures was
greater or equal to 0.01%.
Detection of SIV-specific antibody responses
SIV-specific immunoglobulin G (IgG) in plasma samples
was detected by ELISA as decribed previously [23].
Briefly, Costar EIA/RIA plates (Fisher Scientific, Santa
Clara, CA) were coated with purified whole SIVmac251,
and serial 4-fold dilutions of plasma or serum were
tested. Titers were determined as the highest dilution
with an OD above cut-off value.
Neutralization assay
Neutralization was measured as a reduction in luciferase
reporter gene expression after a single round of infection
in TZM-bl cells as described [74,75]. TZM-bl cells were
obtained from the NIH AIDS Research and Reference
Reagent Program, as contributed by John Kappes and
Xiaoyun Wu. Briefly, 200 TCID50 of virus was incubated
with serial 3-fold dilutions of test sample in duplicate in
a total volume of 150 μl for 1 hr at 37 °C in 96-well flat-
bottom culture plates. Freshly trypsinized cells (10,000
cells in 100 μl of growth medium containing 75 μg/ml
DEAE dextran) were added to each well. One set of con-
trol wells received cells + virus (virus control) and an-
other set received cells only (background control). After
a 48 hour incubation, 100 μl of cells was transferred to a
96-well black solid plates (Costar) for measurements of
luminescence using the Britelite Luminescence Reporter
Gene Assay System (PerkinElmer Life Sciences).
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minescence units (RLU) were reduced by 50% compared
to virus control wells after subtraction of background
RLUs. Assay stocks of molecularly cloned Env-pseudotyped
viruses were prepared by transfection in 293 T cells and
were titrated in TZM-bl cells as described [75]. An assay
stock of uncloned SIVmac251 was produced in H9 cells
and titrated in TZM-bl cells.
Antibody-dependent cell-mediated virus inhibition
Antibody-dependent cell-mediated virus inhibition (ADCVI)
was measured using methods similar to those described
previously [36]. Briefly, target cells were prepared by
infecting CEM.NKr.CCR5 cells (AIDS Reagent Program)
with SHIV or SIV for 72 hours. After washing, target
cells were mixed with fresh human PBMC effector cells
at an effector:target ratio of 10:1 in the presence of test
sera at a final concentration of 1:100. Wells were washed
at day 3 to remove antibody and fresh medium was
then added. Supernatant fluid was assayed at day 7 for
p27 by ELISA (Zeptometrix). Percent inhibition (com-
pared to negative control) was calculated as previously
described [36].
Histopathological evaluation
At time of necropsy, an evaluation of gross pathology
was performed. In addition, tissues were collected in
10% buffered formalin, embedded in paraffin, sectioned,
stained with hematoxylin-eosin, and examined by light
microscopy.
Statistical analysis
Statistical analyses were performed with Prism 5 for
Mac and Instat 3 (GraphPad Software Inc., San Diego,
CA). A value of P of< 0.05 was considered statistically
significant.
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